Long-Term Antipsychotic Treatment in Schizophrenia: Necessity, Reduction, and Shared Decision-Making

Evidence-Based Consensus

Most patients with schizophrenia require indefinite antipsychotic maintenance to prevent relapse. Relapse rates off medication: ~70–80% at 1 year vs. ~20–30% on maintenance.

Guided Dose Reduction / Discontinuation Attempts

May be considered only under close psychiatric supervision if:

  • Sustained remission ≥2–5 years (first episode: longer).
  • Patient strongly desires trial; understands risks.
  • Robust psychosocial support, early warning plan, rapid re-access to care.
  • Slow taper (months); monitor weekly initially.

Risks of Discontinuation

  • Relapse → hospitalization, functional decline, treatment resistance.
  • Suicide risk increases during psychotic relapse.
  • Neuroprogression hypothesis: each episode may cause subtle brain changes.
  • Loss of insight (anosognosia) delays recognition of relapse.

Shared Decision-Making Framework

  1. Discuss evidence, values, preferences.
  2. Define "remission" criteria (symptom scales, functioning).
  3. Agree on taper schedule, monitoring frequency, relapse criteria.
  4. Document plan; involve family/support (with consent).
  5. Re-evaluate regularly—resume medication promptly if early signs emerge.

Never stop antipsychotics abruptly. Always consult your psychiatrist.

Schizophrenia - Related Articles